Trial Profile
A Randomized, Open, Multicenter Trial of Genexol-PM or Paclitaxel Injection combined with Cisplatin for first-line therapy of advanced Non-Small Cell Lung Cancer(NSCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Cisplatin
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Yizhong Bio-technology
- 09 Aug 2022 Results retrospectively analyzing role of Pm-Pac in reducing the toxicity and enhancing the efficacy in NSCLC, presented at the 2022 World Conference on Lung Cancer
- 25 Jul 2022 Results of sub-group analysis assessing metastatic status to identify the potential benefit patients,published in the International Journal of Pharmaceutics.
- 16 Mar 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.